Innovent Biologics
Update in progress1801.HK (HKSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Innovent Biologics is a biopharmaceutical company focused on antibody and protein medicines. It discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases in China, the U.S., and globally. Its portfolio includes TYVYT, BYVASDA, SULINNO, HALPRYZA, PEMAZYRE, and others. It also conducts sales, consulting, and R&D services. Founded in 2011, based in Suzhou.
Company score
- Sentiment
- 1.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.74
- Governance
- 0.29
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.29
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.82
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!